熱門資訊> 正文

Koherus BioSciences 2025年第四季度盈利预览

2026-03-09 05:35

Coherus生物科技(CHRS) 0

Coherus BioSciences (CHRS) is scheduled to announce Q4 earnings results on Monday, March 9th, after market close.
The consensus EPS Estimate is -$0.31 (-10.7% Y/Y) and the consensus Revenue Estimate is $14.09M (-74.0% Y/Y).
Over the last 2 years, CHRS has beaten EPS estimates 13% of the time and has beaten revenue estimates 63% of the time.

More on Coherus BioSciences

Coherus: Downgrade To 'Hold' On Potential Advancement Of Anti-CCR8 CHS-114
Coherus Oncology, Inc. (CHRS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Coherus Oncology: A Two-Pronged March With Mid-2026 Implications
Coherus Oncology prices stock offering to raise $50.1M
Coherus Oncology announces proposed public offering of common stock

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。